Show simple item record

dc.contributor.authorKastelik-Hryniewiecka, A
dc.contributor.authorJewula, P
dc.contributor.authorBakalorz, K
dc.contributor.authorKramer-Marek, G
dc.contributor.authorKuźnik, N
dc.date.accessioned2022-01-25T11:39:25Z
dc.date.available2022-01-25T11:39:25Z
dc.date.issued2021-01-01
dc.identifier.citationInternational journal of nanomedicine, 2021, 16 pp. 8465 - 8483
dc.identifier.issn1176-9114
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4970
dc.identifier.eissn1178-2013
dc.identifier.eissn1178-2013
dc.identifier.doi10.2147/ijn.s336299
dc.identifier.doi10.2147/ijn.s336299
dc.description.abstractRecently, the demand for hybrid PET/MRI imaging techniques has increased significantly, which has sparked the investigation into new ways to simultaneously track multiple molecular targets and improve the localization and expression of biochemical markers. Multimodal imaging probes have recently emerged as powerful tools for improving the detection sensitivity and accuracy-both important factors in disease diagnosis and treatment; however, only a limited number of bimodal probes have been investigated in preclinical models. Herein, we briefly describe the strengths and limitations of PET and MRI modalities and highlight the need for the development of multimodal molecularly-targeted agents. We have tried to thoroughly summarize data on bimodal probes available on PubMed. Emphasis was placed on their design, safety profiles, pharmacokinetics, and clearance properties. The challenges in PET/MR probe development using a number of illustrative examples are also discussed, along with future research directions for these novel conjugates.
dc.formatElectronic-eCollection
dc.format.extent8465 - 8483
dc.languageeng
dc.language.isoeng
dc.publisherDOVE MEDICAL PRESS LTD
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectPositron-Emission Tomography
dc.subjectMagnetic Resonance Imaging
dc.subjectMultimodal Imaging
dc.titleTargeted PET/MRI Imaging Super Probes: A Critical Review of Opportunities and Challenges.
dc.typeJournal Article
dcterms.dateAccepted2021-11-09
rioxxterms.versionVoR
rioxxterms.versionofrecord10.2147/ijn.s336299
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.relation.isPartOfInternational journal of nanomedicine
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging
pubs.publication-statusPublished
pubs.volume16
pubs.embargo.termsNot known
icr.researchteamPreclinical Molecular Imaging
dc.contributor.icrauthorKramer-Marek, Gabriela


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/